| Literature DB >> 24215663 |
Kent Doi, Masahiro Urata, Daisuke Katagiri, Mikako Inamori, Seiichiro Murata, Motoyuki Hisagi, Minoru Ono, Takehiro Matsubara, Takeshi Ishii, Naoki Yahagi, Masaomi Nangaku, Eisei Noiri.
Abstract
INTRODUCTION: Plasma neutrophil gelatinase-associated lipocalin (NGAL) is reportedly useful for post-cardiac surgery acute kidney injury (AKI). Although chronic kidney disease (CKD) is a strong risk factor for AKI development, no clinical evaluation of plasma NGAL has specifically examined AKI occurring in patients with CKD. This study evaluated plasma NGAL in AKI superimposed on CKD after cardiac surgery.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24215663 PMCID: PMC4056897 DOI: 10.1186/cc13104
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Patient characteristics and clinical outcomes
| | |||||
|---|---|---|---|---|---|
| Age (y.o.) | 67.5 (57.8 to 74.0) | 64.5 (53.3 to 73.0) | 74.0 (69.0 to 79.0) | 69.0 (65.5 to 76.0) | 0.0005 |
| Male, | 36 (62.1%) | 16 (80.0%) | 23 (65.7%) | 17 (51.5%) | 0.2 |
| Diabetes, | 24 (41.4%) | 8 (40.0%) | 15 (42.9%) | 12 (36.4%) | 0.95 |
| Hypertension, | 34 (58.6%) | 15 (75.0%) | 24 (68.6%) | 22 (66.7%) | 0.54 |
| Preoperative | | | | | |
| Serum Cre (mg/dl) | 0.75 (0.61 to 0.83) | 0.76 (0.67 to 0.89) | 1.13 (1.01 to 1.38) | 1.39 (1.01 to 1.96) | <0.0001 |
| eGFR (ml/min/1.73 m2) | 75.0 (67.2 to 82.1) | 71.8 (64.1 to 83.6) | 48.5 (35.3 to 53.4) | 36.7 (26.1 to 53.0) | <0.0001 |
| Plasma NGAL (ng/ml) | 61.0 (42.2 to 2.4) | 75.5 (61.0 to 121.0) | 120.0 (66.7 to 224.0) | 209.0 (106.5 to 492.0) | <0.0001 |
| Operation | | | | | |
| Operation time (minutes) | 296 (259 to 358) | 330 (280 to 478) | 304 (257 to 362) | 355 (289 to 420) | 0.064 |
| OPCAB, | 11 (19.0%) | 5 (25.0%) | 10 (28.6%) | 6 (18.2%) | 0.67 |
| CPB, | 47 (81.0%) | 15 (75.0%) | 25 (71.4%) | 27 (81.8) | 0.67 |
| CPB time (minutes) | 151 (119 to 204) | 168 (132 to 286) | 149 (115 to 195) | 170 (110 to 228) | 0.4 |
| Valve surgery, | 17 (29.3%) | 7 (35.0%) | 15 (42.9%) | 12 (36.4%) | 0.62 |
| CABG surgery, | 7 (12.1%) | 1 (5.0%) | 1 (2.9%) | 5 (15.2%) | 0.27 |
| Valve + CABG, | 7 (12.1%) | 4 (20.0%) | 5 (14.3%) | 5 (15.2%) | 0.86 |
| Aortic graft replacement, | 12 (20.7%) | 3 (15.0%) | 2 (5.7%) | 1 (3.0%) | 0.05 |
| Other, | 4 (6.9%) | 0 (0.0%) | 2 (5.7%) | 4 (12.1%) | 0.48 |
| Postoperative | | | | | |
| Body weight gain (kg) | 1.95 (0.77 to 3.30) | 2.96 (1.33 to 4.73) | 2.04 (1.07 to 3.93) | 2.45 (0.64 to 3.88) | 0.66 |
| Need for RRT, | 0 (0.0%) | 2 (10.0%) | 0 (0.0%) | 7 (21.2%) | 0.0001 |
| ICU stay (day) | 3 (2 to 4) | 4 (2 to 10) | 3 (2 to 4) | 4 (2 to 10) | 0.0077 |
CABG, coronary artery bypass grafting; CKD, chronic kidney disease; CPB, cardiopulmonary bypass; OPCAB, off-pump coronary artery bypass grafting; RRT, renal replacement therapy.
Figure 1Study flow diagram. Acute kidney injury (AKI) and chronic kidney disease (CKD) were defined using the AKIN and KDIGO CKD guideline criteria.
Multiple logistic analysis for AKI diagnosis
| Age | -0.025 (-0.065 to 0.015) | 0.22 |
| eGFR | -0.025 (-0.048 to -0.003) | 0.03 |
| Operation time (minutes) | 0.004 (0.001 to 0.008) | 0.03 |
| Plasma NGAL before surgery (ng/ml) | 0.003 (0.001 to 0.007) | 0.03 |
AKI, acute kidney injury; eGFR, estimated glomerular filtration rate; NGAL, neutrophil gelatinase-associated lipocalin.
Figure 2Serum creatinine and plasma NGAL values grouped by AKI severity. Values of serum creatinine (A) and plasma neutrophil gelatinase-associated lipocalin (NGAL) (B) for acute kidney injury (AKI) severity categories (No AKI (n = 89), Mild AKI (n = 39), Severe AKI (n = 14)). #, P <0.05 vs. non-AKI; *, P <0.05 vs. mild AKI.
ROC analysis of plasma NGAL for dialysis requiring AKI
| | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| pre | 122.5 (71.3 to 241.5) | 482.0 (178.4 to 531.0)# | 0.77 | 472 | 67% | 89% | 75 | 30% | 785 | 11% |
| (0.55 to 0.90) | ||||||||||
| 0 h | 125.0 (90.0 to 187.8) | 162.0 (121.0 to 272.0) | 0.66 | 254 | 44% | 89% | 61 | 5% | 469 | 0% |
| (0.44 to 0.83) | ||||||||||
| 2 h | 143.0 (89.7 to 238.8) | 268.0 (171.0 to 419.0)# | 0.75 | 170 | 89% | 61% | 89 | 23% | 861 | 0% |
| (0.54 to 0.88) | ||||||||||
| 4 h | 152.0 (92.9 to 228.8) | 383.0 (235.0 to 619.5)# | 0.81 | 220 | 89% | 75% | 100 | 27% | 608 | 28% |
AKI, acute kidney injury; AUC-ROC, area under the curve operating characteristic curves; CI, confidence interval; NGAL, neutrophil gelatinase-associated lipocalin.
Figure 3Peak time of plasma NGAL and serum creatinine. (A) Time points of the highest plasma neutrophil gelatinase-associated lipocalin (NGAL) and serum creatinine values in mild acute kidney injury (AKI) patients (n = 39). (B) Time lags of the peaks between plasma NGAL and serum creatinine in each AKI patient. Negative values indicate plasma NGAL started to decrease earlier than serum creatinine did. Serum creatinine started to decrease earlier than plasma NGAL in only 8 of 39 mild AKI patients (21%).
Figure 4Plasma NGAL values in AKI and AKI superimposed on CKD Values of plasma neutrophil gelatinase-associated lipocalin (NGAL) for four groups (CKD(-)AKI(-) (n = 54), CKD(-)AKI(+) (n = 20), CKD(+)AKI(-) (n = 39), and CKD(+)AKI(+) (n = 33)). #, P <0.05 vs. CKD(-)AKI(-); *, P <0.05 vs. CKD(+)AKI(-). AKI, acute kidney injury; CKD, chronic kidney disease.
ROC analysis of plasma NGAL in non-CKD and CKD patients
| pre | 0.69 | 73 | 65% | 75% | 52 | 33% | 298 | 15% |
| (0.55 to 0.81) | ||||||||
| 0 h | 0.76 | 102 | 65% | 90% | 49 | 33% | 147 | 23% |
| (0.60 to 0.87) | ||||||||
| 2 h | 0.67 | 142 | 45% | 90% | 48 | 19% | 220 | 13% |
| (0.50 to 0.80) | ||||||||
| 4 h | 0.76 | 72 | 90% | 60% | 49 | 28% | 226 | 15% |
| (0.60 to 0.86) | ||||||||
| 12 h | 0.73 | 90 | 70% | 76% | 48 | 26% | 226 | 15% |
| (0.56 to 0.85) | ||||||||
| 24 h | 0.73 | 91 | 75% | 66% | 47 | 14% | 240 | 20% |
| (0.57 to 0.84) | ||||||||
| 36 h | 0.63 | 113 | 55% | 72% | 44 | 10% | 376 | 5% |
| (0.46 to 0.77) | ||||||||
| 60 h | 0.62 | 124 | 55% | 77% | 35 | 1% | 284 | 20% |
| (0.43 to 0.77) | ||||||||
| | | | | |||||
| pre | 0.71 | 472 | 33% | 100% | 68 | 23% | 341 | 33% |
| (0.56 to 0.82) | ||||||||
| 0 h | 0.75 | 111 | 76% | 63% | 77 | 32% | 233 | 30% |
| (0.61 to 0.85) | ||||||||
| 2 h | 0.75 | 233 | 52% | 94% | 59 | 16% | 241 | 44% |
| (0.61 to 0.85) | ||||||||
| 4 h | 0.74 | 163 | 70% | 69% | 69 | 16% | 286 | 40% |
| (0.60 to 0.84) | ||||||||
| 12 h | 0.72 | 340 | 42% | 97% | 71 | 19% | 322 | 42% |
| (0.58 to 0.83) | ||||||||
| 24 h | 0.77 | 241 | 59% | 85% | 70 | 24% | 363 | 43% |
| (0.63 to 0.87) | ||||||||
| 36 h | 0.71 | 373 | 45% | 94% | 71 | 11% | 379 | 44% |
| (0.56 to 0.82) | ||||||||
| 60 h | 0.66 | 537 | 31% | 97% | 62 | 10% | 432 | 31% |
| (0.51 to 0.78) |
AUC-ROC, area under the curve operating characteristic curves; CI, confidence interval; CKD, chronic kidney disease; NGAL, neutrophil gelatinase-associated lipocalin.